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httpsAbstract: Peripheral arterial diseases comprise different clinical presentations, from cerebrovascular disease down to
lower extremity artery disease, from subclinical to disabling symptoms and events. According to clinical presentation,
the patient’s general condition, anatomical location and extension of lesions, revascularisation may be needed in
addition to best medical treatment. The 2017 European Society of Cardiology guidelines in collaboration with the
European Society for Vascular Surgery have addressed the indications for revascularisation. While most cases are
amenable to either endovascular or surgical revascularisation, maintaining long-term patency is often challenging.
Early and late procedural complications, but also local and remote recurrences frequently lead to
revascularisation failure. The rationale for surveillance is to propose the accurate implementation of preventive
strategies to avoid other cardiovascular events and disease progression and avoid recurrence of symptoms and
the need for redo revascularisation. Combined with vascular history and physical examination, duplex ultrasound
scanning is the pivotal imaging technique for identifying revascularisation failures. Other non-invasive
examinations (ankle and toe brachial index, computed tomography scan, magnetic resonance imaging) at regular
intervals can optimise surveillance in speciﬁc settings. Currently, optimal revascularisation surveillance
programmes are not well deﬁned and systematic reviews addressing long-term results after revascularisation are
lacking. We have systematically reviewed the literature addressing follow-up after revascularisation and we
propose this consensus document as a complement to the recent guidelines for optimal surveillance of
revascularised patients beyond the perioperative period.Keywords: Revascularisation, peripheral arterial disease, follow-up, restenosis
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Peripheral arterial diseases encompass different clinical
presentations, from cerebrovascular disease to lower ex-
tremity artery disease (LEAD), from subclinical to disabling
symptoms and events.1,2 The 2017 European Society of
Cardiology (ESC) guidelines in collaboration with the Euro-
pean Society for Vascular Surgery (ESVS) have addressed
the indications for revascularisation.3 In 2008, over 98 000
endovascular procedures and over 86 000 surgical revas-
cularisations were performed for lower limb arterial disease
Table 1. Checklist of items to be regularly assessed during the
mid and long-term follow-up visits.
Cardiovascular prevention
Tobacco smoking status
 If smoking history: is cessation achieved?
If yes: be supportive
If not: propose speciﬁc intervention and follow-up, refer to
smoking cessation programmes if available
Hypertension
 Check brachial blood pressure bilaterally, at least annually:
blood pressure should be < 140/90 mmHg with the target of
130/80 mmHg if tolerated
 If treated hypertension:
Check diet and drug adherence
Check for other target organ damage (e.g. renal disease)
 If high blood pressure during a visit:
Reassess (ambulatory)
Refer to hypertension specialists
Diabetes
 Check fasting glucose at least annually
 If diabetes:
Check glycated haemoglobin (optimally HbA1c <7%)
 Check treatment and diet adherence
 If newly detected or poorly controlled diabetes:
Refer to diabetes specialist
Cholesterol
 Check lipid levels at least annually: low-density lipoprotein
cholesterol should be <1.8 mmol/L (70 mg/dL) or decreased
at least by 50% compared to the baseline levels
 Assess statin tolerance and compliance
 In the case of signiﬁcant statin intolerance and/or failure to
reach target levels, refer to lipid specialist (consider
ezetemibe and PCSK9 inhibitors)
Other
 Check for adherence to antithrombotic drugs
 Check renal function (urea, creatinine, electrolytes, estimated
glomerular ﬁltration rate)
 Record body mass index, advise optimal body weight
 Re-enforce the importance of regular physical exercise
Symptoms and physical signs related to the revascularisation site
(and contralateral if applicable)
642 Maarit Venermo et al.in Germany alone,4 illustrating the burden of peripheral
revascularisation interventions in Europe.
Maintaining long-term patency after revascularisation is
often challenging. Early and late procedural complications,
but also target and non-target lesion recurrences,
frequently lead to revascularisation failure. Henceforth, the
rationale for surveillance is:
 to detect and treat imminent revascularisation failure
before patency loss and thereby to prevent
complications and redo revascularisations.
 to implement optimal preventive strategies for disease
progression and avoid other cardiovascular events.
This consensus document combines a systematic litera-
ture review on the follow-up beyond the perioperative
period and experts’ inputs to standardise the follow-up of
revascularised patients. It is a complement to the recent
guidelines elaborated through the collaboration of the ESC
and the ESVS.3
The evidence supporting systematic surveillance after
revascularisation is poor, largely due to a lack of good
evidence. In this situation, the opinion of the authors of
this interdisciplinary consensus document is that the
proposed surveillance strategy may be appropriate while
awaiting better quality data to be acquired. Importantly,
the regular follow-up of revascularised patients does not
systematically imply the use of imaging techniques. Clin-
ical assessment and implementation of preventive mea-
sures remain the pillars of the follow-up programme.
These could either be performed by general practitioners
or cardiovascular specialists (cardiologists, vascular phy-
sicians or vascular surgeons) according to the manage-
ment of patients in different countries. The
recommendations here apply irrespective of the health-
care systems.Other cardiovascular conditions
 Assess for cardiovascular symptoms
 Full clinical cardiovascular examination (including 12-lead
ECG)
 Screening for AAA
AAA ¼ abdominal aortic aneurysm; PCSK9 ¼ proprotein convertase
subtilisin/kexin 9; ECG ¼ electrocardiogram.GENERAL ASPECTS
Complications after revascularisation
Revascularisation success is multifactorial, starting with the
indication of the procedure, the quality of the preoperative
assessment and the intervention itself. The postoperative
events are time dependent: the rates of procedure-speciﬁc
adverse events decrease over time while disease-speciﬁc
events are predominant thereafter. The postoperative
complications are usually divided into early (<1 month),
mid (1e12 months) and long-term (>12 months). This pa-
per focuses on the surveillance needed to prevent mid and
long-term adverse events. During these periods the events
are either local, speciﬁc to the revascularised organ/limb
(e.g. bypass thrombosis), or general (e.g. myocardial
infarction). Follow-up should therefore include general
cardiovascular prevention, surveillance and care by a
multidisciplinary team (Table 1). In the case of repetitive
thrombosis after revascularisation, drug adherence,
response to antithrombotic drugs and coagulation disorders
should be investigated.Mid-term complications (1e12 months). Acute thrombosis
of the revascularised site despite antithrombotic therapy is
a major complication after revascularisation. Embolism to
arteries distal to the revascularised site can also cause
ischaemic symptoms.
Restenosis may occur several months after surgical or
endovascular revascularisation.5e7
The primary pathway is intimal hyperplasia, with luminal
area loss despite geometric remodelling. Intimal hyperplasia
lesions are classically detected from a few weeks to 2 years
after intervention.8
Follow-up After Revascularisation for PAD - ESC/ESVS Consensus Document 643Wall shear stress and wall tension stress are considered
as initiators and modulators of intimal hyperplasia.9
Vascular reconstructions such as vein bypass grafts and
stented diseased arteries frequently induce a disordered
ﬂow pattern with low wall shear stress which accelerates
intimal hyperplasia.10 At suture lines the process is also
induced by differential compliance between the prosthesis
and the grafted artery.
Long-term complications (>12 months). Complications
directly related to revascularisation can still occur after one
year, but are progressively dominated by disease progres-
sion and general cardiovascular events, both highly
dependent on the quality of cardiovascular prevention. The
optimal medical management of patients with peripheral
arterial diseases is detailed in the ESC and ESVS guidelines.3Patients’ follow-up
Clinical follow-up. The clinical follow-up includes the
assessment of any symptom or physical sign suggesting
revascularisation failure, or any other cardiovascular con-
dition, as well as ensuring optimal cardiovascular preven-
tion and drug adherence (Table 1). The compliance to
secondary prevention and exercise training, as well as
awareness of revascularisation failure symptoms needing
immediate contact with vascular specialists, are important
factors of long-term success.11e14
Imaging techniques. Because it is non-invasive and widely
available, duplex ultrasound (DUS) performed by experi-
enced operators is usually the ﬁrst-line technique. It can be
repeated over time to detect subclinical abnormalities or
verify whether symptoms are related to revascularisation
failure and/or disease progression. Other functional tests
such as ankle brachial index (ABI) or toe brachial index (TBI)
can optimise the surveillance of lower limbs. Computed
tomography angiography (CTA) and magnetic resonance
angiography (MRA) are mostly limited to the conﬁrmation
and investigation of DUS ﬁndings but can be performed
straight away in urgent cases. Radiation (CTA), contrast
agent nephrotoxicity (CTA, but also MRA) and allergies
should always be considered.EXTRACRANIAL CAROTID ARTERY DISEASE
Mid and long-term outcome after revascularisation
Carotid endarterectomy. In a meta-analysis of 11 rando-
mised clinical trials (RCTs) including 4249 patients with
follow-up over a mean of 47 months, the rate of stenosis
greater than 70% or occlusion after carotid endarterectomy
(CEA) was 5.8% (95% conﬁdence interval [CI] 4.1e8.2).16 In
seven RCTs involving 2810 patients and over a mean of 37
months of surveillance, 5.2% CEA patients with a restenosis
greater than 70% or occlusion had a late ipsilateral stroke
compared with 1.5% in patients without restenosis (odds
ratio [OR] 4.77, 95% CI 2.29e9.92, P < .001).16 In a sec-
ondary analysis of the CREST study, female sex, diabetes,dyslipidaemia and continuing smoking were independent
predictors of restenosis after CEA.15
Carotid artery stenting. After carotid artery stenting (CAS),
most restenoses occur in the ﬁrst year. The rate of recurrent
cerebral ischaemic events is not signiﬁcantly higher in pa-
tients with in-stent restenosis than in those without.17
A meta-analysis of ﬁve RCTs observed that the prevalence
of stenosis greater than 70% (or occlusion) in patients un-
dergoing CAS was 10.0% (95% CI 6.0e16.3) over a mean
follow-up of 62months.16 In the EVA-3S study, the 3-year rate
of restenosis (50%) after CAS was 12.5%,17 with most
restenoses occurring at 12 months or later. However, most of
these restenotic lesions were moderate and severe lesions
were infrequent. Female gender, diabetes, and dyslipidaemia
(but not smoking) were independent predictors of restenosis.
The rate of late ipsilateral stroke in CAS patients with
asymptomatic untreated restenosis greater than 70% is very
low (0.8%over 50months). In fact, 97%of those strokes occur
in patients without signiﬁcant restenosis or occlusion.16
Recurrence or development of atherosclerotic lesions.
Contralateral lesions are more common than ipsilateral
restenosis as their progression depends on the severity of
the disease at the time of intervention. In EVA-3S, most
patients with restenosis after CAS had recurrent stenosis
instead of residual stenosis.17 The rate of contralateral
greater than 70% restenosis or occlusion was 19.8% in the
CAS group and 18.5% in the CEA group. In a cohort of 1639
patients, a 50e69% internal carotid artery (ICA) stenosis
observed in 282 patients progressed to severe 70e99%
stenosis in 32 patients (11.3%) during a mean time of
30.7  26.5 months.18
Whether serial DUS surveillance confers any beneﬁt re-
mains controversial. DUS surveillance enables monitoring of
disease progression in the ipsilateral and contralateral ca-
rotid arteries. Patients with greater than 50% contralateral
stenoses have been reported to be ﬁve times more likely to
progress during follow-up. In some series, progression of
the contralateral stenosis has been associated with an
increased risk of transient ischaemic attack/stroke. In other
series no stroke was associated with a severe (>70%)
contralateral ICA stenosis.19Long-term surveillance methods
Surveillance for restenosis after endarterectomy and
stenting relies mostly on DUS and particularly on the peak
systolic velocity (PSV), the systolic carotid velocity ratio and
the end-diastolic velocity.20,21 Each DUS laboratory should
validate its own criteria. Following intervention (CEA or
CAS), due to structural modiﬁcations of the arterial wall, it
has been proposed that DUS criteria for measuring reste-
nosis severity should be adapted.
After CAS, increased arterial stiffness and reduced
compliance of the ICA has haemodynamic consequences.
DUS velocity criteria for diagnosing greater than 70% in-
stent restenosis is higher than after CEA (Table 2).22,23
Table 2. DUS criteria for restenosis after revascularisation of various arterial territories.
Arterial territory PSV (cm/s) PSV ratio Reference
Carotid artery, stenosis after CEA
>50% 210e220 >2.25 AbuRahma et al., 200974; AbuRahma, 201175
>70e80% 270e280 >3.35 AbuRahma et al., 200974; AbuRahma, 201175
Carotid artery, in-stent stenosis after CAS
>50% >220 >4 Lal et al., 200822; Stanziale et al., 200523
>70% 300 Lal et al., 200822; Stanziale et al., 200523; Zhou et al., 200876
Mesenteric artery, in-stent stenosis
SMA 50% >325 3.5a AbuRahma et al., 201230
Coeliac trunk 50% >270 3.5a AbuRahma et al., 201230
SMA 70% 400e445 8.45a AbuRahma et al., 201230; Soult et al., 201677
Celiac trunk 70% 290e360 5.75a AbuRahma et al., 201230; Soult et al., 201677
Renal artery, in-stent stenosisb
Excludes >60% in-stent stenosis <240 Del Conde et al., 201478
Intermediate zone 240e300 Del Conde et al., 201478
In-stent stenosis (speciﬁcity 94%) 300 Del Conde et al., 201478
>50% >200e350 >4.1a Schäberle et al., 201637
>60% >250 Fleming et al., 201038; Boateng et al., 201336
70% 395 5.1a Chi et al., 200979
Lower extremity, in-stent stenosis
>50% 190 1.5 Baril et al., 200973
>70% 200e250 >2.0 Baril et al., 200973
80% 275 >3.5 Baril et al., 200973
Lower extremity, stenosis of vein bypass graft
>50% 180e300 2e3.5 Tinder et al., 200869
>70e80% 300 >3e3.5 Tinder et al., 200869
DUS ¼ duplex ultrasound; PSV ¼ peak systolic velocity; CEA ¼ carotid endarterectomy; CAS ¼ carotid artery stenting; SMA ¼ superior
mesenteric artery.
a Systolic ratio: target artery compared to PSV in aorta.
b Cut-offs for renal in-stent restenosis are still controversial and should be validated in individual laboratories.78 Higher values of PSV and
changes from baseline PSV increase speciﬁcity.
644 Maarit Venermo et al.In the case of an inconclusive study with DUS, CTA is
preferred as an alternative. MRA is not an option for sur-
veillance after CAS due to stent-related metal artifacts.
Management of restenosis
In the absence of speciﬁc RCTs, symptomatic restenoses
should be treated as soon as possible according to the usual
recommendations regarding ICA stenosis.7
The management of asymptomatic restenoses remains
highly controversial. In a recent meta-analysis by Kumar
et al.,16 the risk of late ipsilateral stroke in patients with an
asymptomatic 70e99% restenosis after CAS was less than
1% at 4 years. Accordingly, any reintervention would be
unlikely to confer any signiﬁcant long-term beneﬁt.
In contrast, the presence of an asymptomatic greater
than 70% restenosis after CEA was associated with a small
but signiﬁcant increase in the risk of late ipsilateral stroke
(about 3.7% increase in absolute risk over 3 years). Conse-
quently, for redo CEA or CAS to confer any long-term
beneﬁt (in terms of late stroke prevention), the proce-
dural death/stroke rate should not exceed 1%.
However, an important patient subgroup to consider for
serial surveillance and reintervention would include CEA and
CAS patients who had a signiﬁcant decrease in cerebral
blood ﬂow during the procedure.7 This might include CEA
patients who developed neurological symptoms, coma or
seizures during carotid clamping under local anaesthesia, orsimilar symptoms during a CAS procedure. Another subgroup
includes CEA patients who developed signiﬁcant electroen-
cephalographic changes and/or a drop in mean middle ce-
rebral artery velocities to less than 15 cm/s during clamping
under general anaesthesia. These patients would be likely to
have a stroke in the case of restenosis progression.7
In light of the ongoing controversy, in patients with an
asymptomatic greater than 70% restenosis after CEA, de-
cisions regarding whether redo CEA or CAS might be
appropriate should involve multidisciplinary team input.
Mid and long-term surveillance protocol
Most RCT protocols for surveillance after CEA or CAS have
involved DUS studies at 1, 3, 6 and 12 months and then
yearly thereafter. Given the low incidence of restenosis and
the very low risk of late ipsilateral stroke in patients with a
restenosis after CEA or CAS, the overall beneﬁt of routine
DUS surveillance remains questionable. However, sub-
groups of patients might carry an increased risk of reste-
nosis, particularly women, patients with diabetes and those
with unfavourable control of their risk factors. DUS also
enables surveillance of disease progression in the contra-
lateral carotid artery.7 In conclusion, although it may remain
controversial, given a favourable beneﬁt/risk ratio, carotid
DUS surveillance at 1, 6, 12 and 24 months is reasonable.
Beyond the initial 2 years after revascularisation, and in the
absence of restenosis over the ﬁrst 2 years and any
Follow-up After Revascularisation for PAD - ESC/ESVS Consensus Document 645signiﬁcant contralateral lesion an annual cardiovascular
check-up remains suitable, but DUS surveillance is not
necessarily needed (Fig. 1).UPPER EXTREMITY ARTERY DISEASE
Mid and long-term outcome after revascularisation
The incidence of main mid and long-term (restenosis or
reocclusion) after revascularisation of upper extremity ar-
tery disease is comparable for both modalities: primary
patency rates of 93% at 2 years and 83e85% at 5 years have
been reported for endovascular treatment (EVT)24,25 versus
96% at 54 months for surgical subclavianecarotid trans-
position.26 Extra-anatomical bypass surgery (mostly
carotidesubclavian bypass) has shown a secondary patency
of 97% after 5 years.27
Signiﬁcant risk factors for restenosis are age, smoking,
small stent diameter, implantation of two or more stents,
inﬂammation (e.g. high sensitivity C-reactive protein level,
leucocytosis) and concurrent carotid or vertebral disease.28Mid and long-term surveillance protocol
As subclavian artery stenosis is an acknowledged marker of
cardiovascular mortality, these patients need the best
medical treatment with a strict control of cardiovascular risk
factors (Table 1).3 Physical examination including bilateral
upper extremity blood pressure (BP) measurement is rec-
ommended at 3, 6 and 12 months, and annually thereafter.
If a restenosis is suspected, DUS is indicated. After stenting
or bypass, DUS surveillance protocols are still debated and
vary in different centres. In speciﬁc cases such as ipsilateral
or contralateral haemodialysis arteriovenous ﬁstula, coro-
nary artery bypass with the ipsilateral internal mammary
artery and bilateral subclavian artery stenosis, serial DUS
surveillance may be beneﬁcial. In these cases, it is advisable
to perform DUS surveillance at 1, 6 and 12 months, and
annually thereafter (Fig. 2).1(–3) mo
If no progression at 2 years, or significant contrala
6 mo
Physical examination
Imaging: DUS
*
Biology: Serum lipids
Figure 1. Surveillance recommendation after
stenting. Although it may remain controversial,
ultrasound (DUS) surveillance at 1, 6 and 12 mon
are available. Beyond the initial 2 years after reva
over the ﬁrst 2 years and any signiﬁcant contra
(e.g. every 2e3 years) can be considered, but a
specialist remains suitable.MESENTERIC ARTERY DISEASE
Imaging follow-up after treatment of acute or chronic
mesenteric artery disease is only needed if the patient
beneﬁts from an early diagnosis of a restenosis or occlu-
sion before symptoms develop.29 In the case of acute
embolic mesenteric ischaemia, appropriate care should
prevent new embolism, by treating the cause and/or
prescribing anticoagulants. If the ﬁrst acute event was due
to atherosclerosis, further bowel loss due to recurrent
mesenteric occlusion might be life threatening. This sup-
ports imaging follow-up in patients who had a mesenteric
artery stenting or surgical procedure after acute mesen-
teric ischaemia.30 We recommend DUS every 3 months
during the ﬁrst year, and then yearly, in line with previous
reports.29,31,32 In the case of recurrent clinical symptoms,
CT is appropriate.
The follow-up strategy is very different after the treat-
ment of chronic mesenteric ischaemia (CMI). Most patients
will develop symptoms of CMI (postprandial pain, weight
loss, and/or diarrhoea) prior to life-threatening bowel
ischaemia. Thus, there is little evidence that routine imaging
follow-up after intervention for CMI results in patient
beneﬁt.29 However, clinical follow-up to secure best medical
treatment and to enable the patient to report symptom
recurrence is highly recommended (Fig. 3).RENAL ARTERY DISEASE
Mid and long-term outcome
In atherosclerotic renal stenosis, a history of cardiovascular
disease (hazard ratio (HR) 2.84) and a 90% or greater ste-
nosis (HR 3.95) are independent predictors of restenosis.33
Fibromuscular dysplasia is also an independent factor of
restenosis after endovascular angioplasty (HR 2.65). In these
patients, primary and assisted primary patency is 95%, 71%
and 50%, and 100%, 100% and 100% at 1, 5 and 9 years,
respectively. Most of the restenoses occur within the ﬁrst 6
months.34teral stenosis, annual DUS not indicated
1 year (Annually)
*
carotid endarterectomy and carotid artery
given a favourable beneﬁt/risk ratio, duplex
ths then yearly is reasonable until new data
scularisation, and in the absence of restenosis
lateral lesion, a less frequent DUS follow-up
n annual appointment with a cardiovascular
1(–3) mo (3–)6 mo 1 year (Annually)
Physical examination: BP measurement; Auscultation
Imaging: DUS
Biology: Serum lipids
Figure 2. Surveillance recommendation after subclavian artery stenting or bypass. Physical
examination including cervical and subclavian auscultation, and bilateral upper extremity
blood pressure (BP) measurement is recommended at 3, 6 and 12 months, and annually
thereafter. In speciﬁc cases (see text), serial duplex ultrasound (DUS) surveillance may be
beneﬁcial. In these cases, we advise DUS surveillance at 1, 6 and 12 months, and annually
thereafter. If there is a suspicion of restenosis with severe symptoms, DUS is indicated at 6
months, and annual DUS may be beneﬁcial in the following indications: haemodialysis ﬁstula,
arteria mammaria coronary artery bypass grafting and subclavian steal syndrome.
646 Maarit Venermo et al.Mid and long-term surveillance protocol
The follow-up of patients after renal revascularisation de-
pends on the cause of the initial renal artery stenosis. It
should be kept in mind that the course of hypertension (i.e.
its cure and/or recurrence) is not always related to renal
restenosis, although it will always be a signal requiring renal
imaging.
Atherosclerotic renal artery stenosis. While the incidence
of restenosis after revascularisation is not well known,
restenosis may be inﬂuenced by the treatment modality
(e.g. angioplasty with or without stenting, surgical repair).35
Surveillance after endovascular intervention, usually
stenting, is based on BP, renal function and DUS.36e38
Currently, no speciﬁc protocol has demonstrated any su-
periority over others. Home-based BP surveillance and
renal function assessment every 3 months during the ﬁrst
year after stenting and every 6 or 12 months thereafter are
recommended. Furthermore, baseline post-procedure DUS
1e3 months after stenting is recommended (Fig. 4).1(–3) mo
Clinical exam
Imaging: DUS
Biology: Serum lipids
Acute embolic
Chronic
Acute on
chronic
9 mom6
Figure 3. Surveillance recommendation after me
of embolic acute mesenteric ischaemia, appropri
treating the cause and/or prescribing anticoagu
sclerosis (acute on chronic), trimestrial duplex ult
annually is recommended. There is little evidenc
vention for chronic mesenteric ischaemia results i
recommended to secure best medical treatment, in
patient to report symptom recurrence.Thereafter the imaging follow-up should be clinically
driven (changes in kidney function, BP control, antihyper-
tensive therapy requirements or occurrence of heart fail-
ure). If a restenosis is suspected, DUS should be performed
as the ﬁrst imaging option to assess renal arteries and
kidneys. The criteria of in-stent restenosis (ISR) are pre-
sented in Table 2. Changes from baseline post-stenting PSV
add sensitivity.
If the diagnosis by DUS remains doubtful and clinical
suspicion is strong, an angiogram with pressure gradient
measurement is recommended. CTA demonstrates a high
accuracy for detecting restenosis, but should be limited to
inconclusive DUS and/or preoperatively, in order to avoid
renal damage.37 Due to stent-related metal artifacts, renal
MRA is often suboptimal.
A similar follow-up protocol is recommended for surgical
repair.
Although the optimal treatment of restenosis is still
debated,39 there is a trend favouring the repetition of the
initial EVT, or bypass surgery following two failures. The ﬁnalo )yllaunnA(raey1
senteric artery stenting or bypass. In the case
ate care should prevent a new embolism, by
lants. If the acute event was due to athero-
rasound (DUS) during the ﬁrst year and then
e that routine imaging follow-up after inter-
n patient beneﬁt. Annual clinical follow-up is
cluding smoking cessation, and to enable the
Figure 4. Surveillance recommendation after renal artery stenting (RAS) or bypass. Fibro-
muscular dysplasia (FMD): Currently the optimal post-revascularisation monitoring protocol
is not well evidenced. We propose a duplex ultrasound (DUS) at baseline, every 6 months for
the ﬁrst 24 months and then annually. Blood pressure (BP) and plasma creatinine levels must
be carefully followed with a ﬁrst control one month after revascularisation, every 3 months
during the ﬁrst year and twice a year thereafter. Atherosclerotic lesions: We recommend a
home-based BP surveillance and renal function testing every 3 months during the ﬁrst year
after stenting and every 6e12 months thereafter. Furthermore, baseline post-procedure and
DUS 1e3 months after stenting or surgical repair is recommended. Thereafter the imaging
follow-up should be clinically driven (changes in kidney function, BP control, antihyperten-
sive therapy requirement or heart failure). If there is a suspicion of restenosis in BP or renal
function testing, DUS is recommended. eGFR ¼ estimated glomerular ﬁltration rate.
Follow-up After Revascularisation for PAD - ESC/ESVS Consensus Document 647decision should be guided by a consensus between ne-
phrologists, interventionists and vascular surgeons.37
Fibromuscular dysplasia. The optimal post-revascularisation
surveillance protocol is not well evidenced. DUS is recom-
mended at 1e3 months, every 6 months for the ﬁrst 24
months and then annually (Fig. 4). BP and plasma creatinine
levels must be carefully followed after the ﬁrst month, and
then every 3 months during the ﬁrst year and twice a year
thereafter. After a successful revascularisation, antihyper-
tensive medication will probably need to be reduced or
stopped, at least temporally. As restenosis mostly occurs
within the ﬁrst 6 months, DUS will be performed earlier in
the case of BP and/or plasma creatinine elevation.3,40 CTA
or MRA are not recommended for routine surveillance in
the absence of untreated aneurysms.
Any signiﬁcant restenosis should lead to angiography and
angioplasty. CTA or MRA might be needed to conﬁrm the
DUS diagnosis and better assess potential technical issues.
Surgery should be considered in the case of complex lesions
or recurrent stenosis.
LOWER EXTREMITY ARTERY DISEASE
The revascularisation indications in LEAD relate primarily to
chronic limb-threatening ischaemia (CLTI), and severe,
disabling claudication, especially if medical management
and exercise therapy are ineffective. Follow-up may differ
according to the indication for revascularisation, the type of
revascularisation and the patient’s physical condition. The
aim of surveillance is to prevent revascularisation failure
and eventually amputation. The surveillance should not only
focus on the revascularisation site, but must include the
completely revascularised limb as well as the contralaterallimb, along with a general clinical cardiovascular surveil-
lance (Table 1).
Mid and long-term outcome
After surgery. The ﬁrst-year incidence of vein graft stenosis
is 20%.41,42 During the ﬁrst 3 months, bypass stenosis/
thrombosis can be due to technical issues. Almost 15% of
graft failures occur during the ﬁrst month; almost 80%
during the ﬁrst 2 years and no more than 5% thereafter.43,44
During the mid-term period, bypass failure is predominantly
associated with intimal hyperplasia causing anastomotic
stenosis, graft stenosis or occasionally with ﬁbrosis of the
valve cusp. These are the most common causes of poten-
tially identiﬁable and treatable graft stenoses.
The majority of signiﬁcant graft stenoses are asymp-
tomatic and only 11e38% can be diagnosed by ischaemic
symptoms or decreased pulse on physical examination.45,46
ABI drop greater than 0.15 has been proposed to detect
revascularisation failure, but its sensitivity is poor. Hence,
the use of ABI alone to monitor a revascularised limb should
be avoided, and it should always be used in combination
with DUS.47 In patients with abnormal DUS and ABI the
reported graft failure is 66% in the 3-month period
following measurements.48 Angiography (CTA, MRA or dig-
ital subtraction angiography) is proposed only if there are
clinical and/or ultrasound data suggesting graft failure or
disease progression.
Signiﬁcant (>50%) vein graft or anastomosis stenoses are
usually treated by EVT. Studies comparing endovascular
techniques are scarce.49 In the case of multiple restenosis,
surgical revision and replacement of the diseased segment
with a vein interposition or a jump graft/patch angioplasty
in the anastomotic stenosis is recommended. In the case of
Intermittent claudication
CLTI
*
1(-3) mo
Imaging: DUS up to 24 mo
Biology: Serum lipids
DUS recommended up to 2 years after bypass
6 mo 1 year (Annually)
*
*
*
*
Physical examination: BP, ABI + TP; In CLTI: WIfI-classification, TcPO2 if needed
Figure 5. Surveillance recommendation after vein bypass for lower extremity artery disease.
Surveillance includes clinical examination, ankle brachial index (ABI) (or toe pressure [TP]/toe
brachial index [TBI]) measurement and duplex ultrasound (DUS). Although solid scientiﬁc
evidence is lacking, there is consensus that the ﬁrst post-discharge test should be performed
within 4e6 weeks, thereafter at 3 months, 6 months, 12 and 24 months after bypass surgery. If
a new intervention is performed for graft stenosis or occlusion, the surveillance programme is
re-initiated from the start. Clinical surveillance is lifelong and of paramount importance
especially for patients with chronic limb-threatening ischaemia (CLTI) (see Table 1). If there is
a suspicion of restenosis, an angiogram is recommended. WIﬁ ¼ wound, ischaemia, foot
infection; TcPO2 ¼ transcutaneous oxygen tension; BP ¼ blood pressure.
648 Maarit Venermo et al.vein graft occlusion, thrombolysis should be performed
within 6e48 h after symptom onset with treatment of the
defect, but re-thrombosis is not rare even though the un-
derlying cause has been corrected. For prosthetic bypasses
(polytetraﬂuoroethylene, dacron), thrombolysis can usually
be effective up to 2 weeks. The intra-arterial catheter for
thrombolysis is usually introduced inside the graft by the
contralateral groin. Low dose alteplase (1 mg/h) for 12e
48 h is a commonly used protocol.
After EVT for vein graft stenosis, a 1e6-month dual anti-
platelet therapy with aspirin and clopidogrel is usually pre-
scribed unless the patient has an increased bleeding risk.3
After revascularisation following vein graft occlusion,
anticoagulants (usually low molecular weight heparin) are
combined with antiplatelet therapy (aspirin or clopidogrel).
The duration of the anticoagulation varies between one
month and lifelong and should be tailored according to the
cause of the graft occlusion, to previous thrombotic events
(particularly previous graft occlusions) and to the patient’s
bleeding risk. In long-term anticoagulation treatment,
vitamin K antagonists are used.
After prosthetic bypass occlusion, long-term anti-
coagulation therapy should be considered.50 Considering
the lack of data on direct oral anticoagulant use for this
indication, long-term vitamin K antagonists are usually
recommended.
If the autologous vein bypass graft has been uneventful
for 12 months, late issues are scarce. After the ﬁrst post-
operative year, the annual incidence of autologous graft
failure is estimated to be approximately 1e2%.51,52 After
venous bypass surgery, 5-year follow-up has shown LEAD
progression in 19% of cases.53 For prosthetic grafts, late
occlusion rates are higher, as 40% of femoropopliteal
prosthetic grafts are expected to occlude within 5 years.54
Anastomotic pseudoaneurysms are rare.
The progression of atherosclerosis can be seen either in
the inﬂow or outﬂow vessels. Prosthetic grafts may showlate anastomosis stenoses. In the case of severe progression
of atherosclerosis in the inﬂow or outﬂow arteries, typical
symptoms of LEAD (claudication, rest pain, tissue lesion) or
graft occlusion may occur. However, in many cases disease
progression can be asymptomatic. Typically, these patients
show up when LEAD symptoms appear. Imaging is indicated
irrespective of symptoms. If bypass patency is threatened,
intervention is usually recommended even if clinical symp-
toms are mild, according to the multidisciplinary team
assessment.
After EVT. The most common mid-term complications after
EVT are restenosis and occlusion of the treated vessel
segment, ranging from approximately 5% in the pelvic re-
gion up to over 50% in the infrapopliteal arteries. Recur-
rence of symptoms may also be due to disease progression
above or below the angioplasty site.55
Restenosis is mainly related to intimal hyperplasia at the
balloon dilation site and at the proximal or distal end of the
stent. Restenosis can also be related to initial suboptimal
procedural results (residual dissection, >50% residual ste-
nosis, distal embolisation, acute recoil, or inadequate inﬂow
or outﬂow treatment).56,57 Restenosis/occlusion can be
asymptomatic or can cause typical symptoms (claudication,
recurrence of leg pain and/or non-healing lesions) requiring
reintervention. Pulse palpation and ABI in combination with
DUS are used for follow-up (Fig. 5). In the case of recurrent
claudication, the treadmill test with post-exercise ABI can
assess the functional severity.3 Stent thrombosis usually
presents with acute worsening of symptoms and sometimes
acute limb ischaemia.
Endovascular reintervention is the ﬁrst-line treatment
option in clinically relevant restenosis or occlusion. If EVT is
not successful, bypass surgery might be considered. After a
second failure of EVT, a multidisciplinary vascular team
should evaluate the patient.3 After endovascular reinter-
vention, dual antiplatelet therapy with aspirin and
Follow-up After Revascularisation for PAD - ESC/ESVS Consensus Document 649clopidogrel should be considered for a longer period than
after the ﬁrst intervention, taking into account the patient’s
bleeding risk and the lesion location, with shorter duration
in proximal versus distal lesions. A period of at least 3
months is recommended. However, due to the lack of evi-
dence for these recommendations, this is based on clinical
experience and expert opinion.
The long-term natural history of LEAD following EVT has
been poorly investigated. Unlike surgery, no plateau phase
is seen in the incidence of EVT failure after the ﬁrst months,
but there is a relatively constant failure rate for at least the
ﬁrst 5 years. The failure rate is quite low for iliac arteries,
but deﬁnitely higher for femoropopliteal and for below the
knee arteries (Fig. 6).
Severe restenosis accounts for the majority of reinter-
ventions; because restenosis is usually symptomatic, the
role of DUS surveillance in guiding reinterventions is
questionable.58
Beyond one year, the reported incidence of late stent
thrombosis is 10% at a median follow-up of 19 months in
the femoropopliteal segment.58 It is not always preceded by
severe in-stent restenosis, making this complication un-
predictable by means of DUS surveillance.
After iliac stenting, the reported reintervention rate at 5
years is as low as 2.5% for primary stenotic lesions and
12.5% for primary occlusions, with a 6-year primary patency
rate of 82.4% and 77.7%, respectively.59 In the femo-
ropopliteal segment, most studies reporting long-term data
include only patients with Trans-Atlantic Consensus (TASC)
A and B lesions. In this setting, the average 5-year freedom
from target lesion revascularisation has been reported to be
approximately 70e80%.60Intermittent claudication
CLTI
1(–3) mo (3–)6 mo
*
* DUS should be repeated after discharge only in ca
Physical examination: BP, ABI + TP; In CLTI: WIf
Imaging: DUS up to 24 mo
Biology: Serum lipids
Figure 6. Surveillance recommendation after endo
artery disease. Surveillance includes clinical assess
ankle brachial index (ABI) (or toe pressure [TP]
duplex ultrasound (DUS). Further tests such as to
sion (TcPO2) may be needed in the case of chro
surveillance after EVT by means of an initial test p
recommended; if results are normal, subsequent e
months; while if the initial DUS is abnormal, rein
decided on a case-by-case basis. The usefulness o
larised patients who remain asymptomatic has nev
as routine surveillance; however, these patients
veillance focused on risk factor management, exer
basis. Clinical surveillance is lifelong and of param
CLTI (Table 1). If there is a suspicion of restenos
recommended. WIfI ¼ wound, ischaemia, foot infeVery few studies describe long-term results after infra-
popliteal EVT; 5-year primary patency ranges from 38% in
one study on balloon angioplasty,61 to 9% with bare metal
stents and 12% with drug-eluting stents in another trial.62
Importantly, 5-year freedom from major amputation
(range 66e81%) was deﬁnitely higher than primary patency
in both trials.
Late complications are usually suspected by the reoc-
currence of symptoms. DUS is the mainstay for the diag-
nosis and guidance of treatment. Restenosis after EVT is
usually amenable to repeat balloon angioplasty with or
without stenting or to bypass in the case of repeated fail-
ure. Acute thrombosis can be treated by aspiration and/or
thrombolysis, but revascularisation by EVT is much more
difﬁcult if the thrombosis is old. Reintervention should be
decided on a case-by-case basis, taking into account the
severity of symptoms, the general condition of the patient
(renal function, bleeding risk) and the likelihood of success
(history of recurrent restenosis) preferably by the multi-
disciplinary team.
Disease progression. Atherosclerosis involves the whole
vascular tree and coexisting atherosclerotic manifestations
in other vascular beds are very common in patients with
LEAD.3 Patients with multisite artery disease more often
have progressive atherosclerosis in all vascular beds and
have a higher incidence of cardiovascular events.63,64
Therefore, it is of paramount importance to prevent
atherosclerosis progression by regularly monitoring risk
factor modiﬁcation, exercise training and medical therapy.
In patients with intermittent claudication, disease pro-
gression to CLTI may be underestimated. In a meta-analysis   
1 year (Annually)
se of symptom recurrence
I-classification, TcPO2 if needed
vascular treatment (EVT) for lower extremity
ment looking for recurrent symptoms or signs,
/toe brachial index [TBI]) measurement and
e pressure and/or transcutaneous oxygen ten-
nic limb-threatening ischaemia (CLTI). DUS
erformed between discharge and one month is
xaminations should be performed at 6 and 12
tervention or closer DUS follow-up should be
f a yearly DUS beyond 12 months in revascu-
er been proved, and cannot be recommended
require a comprehensive cardiovascular sur-
cise training and medical therapy on a yearly
ount importance especially for patients with
is which requires treatment, an angiogram is
ction; BP ¼ blood pressure.
650 Maarit Venermo et al.of studies conducted between 1990 and 2015, 21% of pa-
tients with intermittent claudication were diagnosed with
CLTI during a 5-year follow-up period and 4e27% of them
had amputations.55 On the other hand, a recent RCT on EVT
for femoropopliteal disease showed a rate of persistent or
worsening claudication or CLTI at 5 years of 20% in the DES
arm and of 41% in the balloon angioplasty with or without
bare metal stent arm.60 Therefore, the regular follow-up
programme should involve assessment for atherosclerosis
in both lower limbs and clinical manifestations of other
clinical sites such as coronary arteries, carotid arteries and
the abdominal aorta.Mid and long-term surveillance protocol
After bypass surgery. Graft failure should be identiﬁed
before occlusion occurs. Not all graft stenoses progress to
occlusion: in a study of 63 duplex-veriﬁed stenosis with over
50% of diameter reduction, 43% resulted in bypass throm-
bosis during the following 8 months.65 Low ﬂow is also
reported as an indicator of an increased risk of graft
failure.66
Surveillance includes clinical examination, ABI (or TBI)
measurement and DUS. Optimally, detailed description of the
procedure and previous DUS examinations should be available
for the sonographer. In a meta-analysis of 15 RCTs, DUS sur-
veillance after venous bypass surgery did not improve graft
patency and was associated with a statistically non-signiﬁcant
decrease in the amputation rate (OR 0.7, 95% CI 0.23e2.13).67
In another retrospective analysis on 1404 bypass patients
scheduled for routine DUS surveillance, 200 (14%) patients
sustained graft occlusion. In a multivariate analysis, non-
adherence to a DUS surveillance programme was indepen-
dently associatedwith venous graft occlusion (HR 1.58, 95% CI
1.10e2.27).68 This cannot only be due to DUS surveillance but
also to treatment adherence and accurate clinical follow-up,
emphasising the importance of long-term medical manage-
ment of these patients beyond imaging.
In the lack of solid evidence, there is a consensus that the
ﬁrst post-discharge test should be performed within 4e6
weeks, thereafter at 3 months, 6 months, 12 and 24 months
after bypass surgery. If a reintervention is performed for
graft stenosis or occlusion, the surveillance programme
should be reinitiated from the start. Although DUS sur-
veillance may stop after 24 months, clinical surveillance is
lifelong and of paramount importance especially for pa-
tients with CLTI (Fig. 5, Table 1).
Some features are considered as high risk for graft
thrombosis and requiring closer attention: spliced grafts,
poor quality vein (varicose lesions, vein with a thick wall,
post-thrombotic manifestations, vein diameter <3 mm),
poor run-off or secondary bypass surgery.69,70 Also, an
abnormal DUS scan at 4e8 weeks has been predictive of
later graft failure. McBride et al.70 proposed a decision tree
to identify high-risk grafts for DUS surveillance. In the sur-
veillance of 249 bypass grafts the sensitivity and speciﬁcity
of their model for the prediction of graft stenosis occlusionwere 95% and 52%, respectively; the negative predictive
value being 97%.66
After EVT. Surveillance includes clinical assessment looking
for recurrent symptoms or signs, ABI (or TBI) measurement
and DUS. Although ABI adds signiﬁcant information to
clinical examination, it correlates poorly with angiographic
stenosis, and a signiﬁcant decrease in ABI (>0.15) may not
be present until a greater than 60% stenosis exists. How-
ever, it may be useful to perform ABI measurements within
one month of EVT, at 6 and 12 months. Duplex scan is more
sensitive to detect restenosis, but to date there is no clear
evidence showing that DUS surveillance improves limb
outcomes. Initial studies indicated that an abnormal ﬁrst
DUS (1e30 days after EVT) was associated with higher
target lesion revascularisation at one year.71,72 More
recently, DUS surveillance has been reported to predict
severe in-stent restenosis with a speciﬁcity greater than
90%.73 However, a DUS-based surveillance protocol at 3, 6
and 12 months after superﬁcial femoral artery (SFA) or
popliteal angioplasty with or without stenting reported a
sensitivity and a speciﬁcity of 88% and 60%, respectively, to
predict complete occlusion with 2 years of follow-up.58
About half of severe restenoses present with ischaemic
symptoms requiring reintervention, regardless of DUS
ﬁndings. Whether identifying asymptomatic severe reste-
noses should lead to immediate reintervention or closer
follow-up is uncertain. If restenosis requiring treatment is
suspected in DUS, a digital subtraction angiogram is rec-
ommended and re-EVT if possible at the same session.
In conclusion, based on consensus rather than strong
evidence, we recommend DUS surveillance after EVT by
means of an initial test performed between discharge and
one month; if the results are normal, DUS is recommended
if symptoms reappear. However, if the initial DUS is
abnormal, reintervention or closer DUS follow-up should be
discussed on a case-by-case basis. The usefulness of a yearly
DUS beyond 12 months in revascularised patients who
remain asymptomatic has never been proved, and cannot
be recommended as routine surveillance. These patients
require a comprehensive cardiovascular surveillance
focused on risk factor management, exercise training and
medical therapy on a yearly basis.
Special aspects after revascularisation for CLTI
After revascularisation for CLTI, closer follow-up and wound
care is recommended until wounds are healed, and 30-day,
3e6 and 12-month surveillance is recommended. After
wound healing, annual appointments with vascular physi-
cians/surgeons should be organised to check for symptoms,
foot condition, ABI, cardiovascular risk factors as well as
availability to check toe pressures and transcutaneous ox-
ygen tension (TcPO2) if needed (Table 1).
CONCLUSION
This paper aims to provide a standardised follow-up
approach, based on a combination of evidence and
Follow-up After Revascularisation for PAD - ESC/ESVS Consensus Document 651authors’ expertise, emphasising the importance of a multi-
disciplinary management of these patients with an optimal,
clinically reasonable and cost-effective strategy. This
collaborative work highlights many gaps in the evidence and
suggests collaborative research to provide further data and
evidence in this setting.APPOINTED REVIEWERS
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